Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation

Ching Yih Lin, Yu Feng Tian, Li Ching Wu, Li Tzong Chen, Li Ching Lin, Chung Hsi Hsing, Sung Wei Lee, Ming Jen Sheu, Hao Hsien Lee, Yu Hui Wang, Yow Ling Shiue, Wen Ren Wu, Hsuan Ying Huang, Han Ping Hsu, Chien Feng Li, Shang Hung Chen

研究成果: 雜誌貢獻文章同行評審

24 引文 斯高帕斯(Scopus)

摘要

Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT. Methods: Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival. Results: Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced posttreatment tumour status (T3, T4, p

原文英語
頁(從 - 到)687-692
頁數6
期刊Journal of Clinical Pathology
65
發行號8
DOIs
出版狀態已發佈 - 八月 2012
對外發佈Yes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

指紋 深入研究「Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation」主題。共同形成了獨特的指紋。

引用此